Company registration number:
15112743
Natco Pharma UK Limited
Filleted financial statements
31 March 2025
Natco Pharma UK Limited
Contents
Directors and other information
Directors responsibilities statement
Statement of financial position
Statement of changes in equity
Notes to the financial statements
Natco Pharma UK Limited
Directors and other information
|
|
|
|
|
Directors |
Veera Venkata Narasimha Appa Rao Sannidhanam |
|
|
|
Praveen Kumar Barur |
|
|
|
|
|
|
|
|
|
|
Company number |
15112743 |
|
|
|
|
|
|
|
|
|
|
Registered office |
Amba House, 4th Floor |
|
|
|
15 College Road |
|
|
|
Middlesex |
|
|
|
Harrow |
|
|
|
HA1 1BA |
|
|
|
|
|
|
|
|
|
|
Auditor |
Nagle James Associates Limited |
|
|
|
Amba House, 4th Floor, |
|
|
|
Kings Suite, 15 College Road |
|
|
|
Harrow |
|
|
|
Middlesex |
|
|
|
HA1 1BA |
|
|
|
|
|
Natco Pharma UK Limited
Directors responsibilities statement
Year ended 31 March 2025
The directors are responsible for preparing the directors report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the profit or loss of the company for that period.
In preparing these financial statements, the directors are required to:
-
select suitable accounting policies and then apply them consistently;
-
make judgments and accounting estimates that are reasonable and prudent; and
-
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Natco Pharma UK Limited
Statement of financial position
31 March 2025
|
|
|
2025 |
|
|
|
2024 |
|
|
|
|
Note |
£ |
|
£ |
|
£ |
|
£ |
|
|
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
|
Debtors |
|
4 |
787 |
|
|
|
213 |
|
|
|
Cash at bank and in hand |
|
|
832,191 |
|
|
|
805,152 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
832,978 |
|
|
|
805,365 |
|
|
|
Creditors: amounts falling due |
|
|
|
|
|
|
|
|
|
|
within one year |
|
5 |
(
1,313) |
|
|
|
(
4,083) |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
Net current assets |
|
|
|
|
831,665 |
|
|
|
801,282 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
Total assets less current liabilities |
|
|
|
|
831,665 |
|
|
|
801,282 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
_______ |
|
|
|
_______ |
|
Net assets |
|
|
|
|
831,665 |
|
|
|
801,282 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
|
Capital and reserves |
|
|
|
|
|
|
|
|
|
|
Called up share capital |
|
6 |
|
|
1,228,810 |
|
|
|
1,228,810 |
|
Profit and loss account |
|
|
|
|
(
397,145) |
|
|
|
(
427,528) |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
Shareholders funds |
|
|
|
|
831,665 |
|
|
|
801,282 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
These financial statements were approved by the
board of directors
and authorised for issue on
16 May 2025
, and are signed on behalf of the board by:
Veera Venkata Narasimha Appa Rao Sannidhanam
Director
Company registration number:
15112743
Natco Pharma UK Limited
Statement of changes in equity
Year ended 31 March 2025
|
|
Called up share capital |
|
Profit and loss account |
Total |
|
|
|
|
|
|
|
£ |
|
£ |
£ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 4 September 2023 |
|
- |
|
- |
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit/(loss) for the year |
|
|
|
(
427,528) |
(
427,528) |
|
|
|
|
|
|
|
_______ |
|
_______ |
_______ |
|
|
|
|
|
|
Total comprehensive income for the year |
|
- |
|
(
427,528) |
(
427,528) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issue of shares |
|
1,228,810 |
|
|
1,228,810 |
|
|
|
|
|
|
|
_______ |
|
_______ |
_______ |
|
|
|
|
|
|
Total investments by and distributions to owners |
|
1,228,810 |
|
- |
1,228,810 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
_______ |
|
_______ |
_______ |
|
|
|
|
|
|
At 31 March 2024 and 1 April 2024 |
|
1,228,810 |
|
(
427,528) |
801,282 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit/(loss) for the year |
|
|
|
30,383 |
30,383 |
|
|
|
|
|
|
|
_______ |
|
_______ |
_______ |
|
|
|
|
|
|
Total comprehensive income for the year |
|
- |
|
30,383 |
30,383 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
_______ |
|
_______ |
_______ |
|
|
|
|
|
|
At 31 March 2025 |
|
1,228,810 |
|
(
397,145) |
831,665 |
|
|
|
|
|
|
|
_______ |
|
_______ |
_______ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Natco Pharma UK Limited
Notes to the financial statements
Year ended 31 March 2025
1.
General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Amba House, 4th Floor, 15 College Road, Middlesex, Harrow, HA1 1BA.
2.
Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3.
Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
The amounts are rounded to the nearest whole number and no other rounding is used.
Going concern
The directors have considered cashflow requirements for the period 12 months from approval of the financial statements to assess the working capital needs of the company. This confims that the company will have sufficient working capital within the period reviewed and will be able to meet its liabilities as they fall due, subject to support of other group companies and its ultimate parent company.Confirmation of such support has been received from the ultimate parent company.Accordingly the directors believe it is appropriate to prepare the financial statements on a going concern basis.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.
Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.
Debt instruments are subsequently measured at amortised cost.
4.
Debtors
|
|
|
2025 |
2024 |
|
|
|
£ |
£ |
|
Other debtors |
|
787 |
213 |
|
|
|
_______ |
_______ |
|
|
|
|
|
5.
Creditors: amounts falling due within one year
|
|
|
2025 |
2024 |
|
|
|
£ |
£ |
|
Other creditors |
|
1,313 |
4,083 |
|
|
|
_______ |
_______ |
|
|
|
|
|
6.
Called up share capital
Issued, called up and fully paid
|
|
|
2025 |
|
|
|
2024 |
|
|
|
|
|
No |
|
£ |
|
No |
|
£ |
|
Ordinary shares of £
1.00 each |
|
1,228,810 |
|
1,228,810 |
|
1,228,810 |
|
1,228,810 |
|
|
|
_______ |
|
_______ |
|
_______ |
|
_______ |
|
|
|
|
|
|
|
|
|
|
7.
Summary audit opinion
The auditor's report dated
16 May 2025
was unqualified.
The senior statutory auditor was
Kaushik Nathwani
for and on behalf of
Nagle James Associates Limited
8.
Related party transactions
The company has taken advantage of the exemption under FRS 102 Section 33.1A not to disclose transactions with the parent company.
The company's ultimate parent undertaking and immediate parent at the balance sheet date was Natco Pharma Limited, a company incorporated in India and it holds 100% of issued share capital. The company's registered address is Natco House, Road No.2, Banjara Hills, Hyderabad, Telengana - 500034, India.